Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 1/20 | 0.44 |
| ▸ | VDR | P11473 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10339892 | 0.93 | ALDH1A1 (0.41) | AGERVDRGAASTAT3ALDH1A1 | |
| SCHEMBL116604 | 0.91 | AGER (0.41) | AGERVDRGAASTAT3ALDH1A1 | |
| SCHEMBL25345480 | 0.91 | AGER (0.41) | AGERVDRGAASTAT3ALDH1A1 | |
| SCHEMBL30802773 | 0.91 | AGER (0.41) | AGERVDRGAASTAT3ALDH1A1 | |
| SCHEMBL116676 | 0.91 | AGER (0.41) | AGERVDRGAASTAT3ALDH1A1 | |
| SCHEMBL17396769 | 0.90 | CA12 (0.40) | AGERVDRGAASTAT3ALDH1A1 | |
| SCHEMBL28655071 | 0.90 | DHODH (0.42) | AGERVDRGAASTAT3ALDH1A1 | |
| SCHEMBL17396847 | 0.90 | CA12 (0.40) | AGERVDRGAASTAT3ALDH1A1 | |
| SCHEMBL336511 | 0.89 | AGER (0.44) | AGERVDRGAASTAT3ALDH1A1 | |
| SCHEMBL17427977 | 0.89 | CA12 (0.45) | AGERVDRGAASTAT3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358929-B2 | NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2025-07-15 | — | — | US | disclosed |
| US-20240294546-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2024-09-05 | — | — | US | disclosed |
| EP-3558318-B1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2023-12-20 | — | — | EP | disclosed |
| US-11807650-B2 | NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2023-11-07 | — | — | US | disclosed |
| US-11807650-B2 | NMDA receptor modulators and uses thereof | NOVARTIS AG (CH) | 2023-11-07 | — | — | US | disclosed |
| US-11679095-B2 | Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases | THE GENERAL HOSPITAL CORPORATION (US) | 2023-06-20 | — | — | US | disclosed |
| US-20220153755-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2022-05-19 | — | — | US | disclosed |
| US-11274107-B2 | NMDA receptor modulators and uses thereof | CADENT THERAPEUTICS, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-10738063-B2 | 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds | PFIZER INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20200087323-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2020-03-19 | — | — | US | disclosed |
| US-20160263257-A1 | CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT | THE GENERAL HOSPITAL CORPORATION | 2016-09-15 | — | — | US | disclosed |
| EP-2944637-A1 | NITROGEN-CONTAINING HETEROCYLIC COMPOUND OR SALT THEREOF | FUJIFILM Corporation (JP) | 2015-11-18 | — | — | EP | disclosed |
| EP-2944637-A1 | NITROGEN-CONTAINING HETEROCYLIC COMPOUND OR SALT THEREOF | FUJIFILM Corporation (JP) | 2015-11-18 | — | — | EP | disclosed |
| WO-2014109414-A1 | NITROGEN-CONTAINING HETEROCYLIC COMPOUND OR SALT THEREOF | 富士フイルム株式会社 (JP) | 2014-07-17 | — | — | WO | disclosed |
| US-20140140927-A1 | CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT | THE GENERAL HOSPITAL CORPORATION (US) | 2014-05-22 | — | — | US | disclosed |
| US-20120058049-A1 | CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT | THE GENERAL HOSPITAL CORPORATION | 2012-03-08 | — | — | US | disclosed |
| WO-2010088455-A2 | CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT | THE GENERAL HOSPITAL CORPORATION (US) | 2010-08-05 | — | — | WO | disclosed |
| US-20090227616-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION, A CORPORATION | 2009-09-10 | — | — | US | disclosed |
| EP-1948185-A2 | INHIBITORS OF AKT ACTIVITY | SmithKline Beecham Corporation (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007058852-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227616-A1 | INHIBITORS OF AKT ACTIVITY | PI4KB, PIK3CA, AKT2 | AGER 4297/4885VDR 4415/4885GAA 2624/4885 |
| US-11807650-B2 | NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN2C | AGER 684/4885VDR 289/4885GAA 3389/4885 |
| US-11274107-B2 | NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN2C | AGER 684/4885VDR 289/4885GAA 3389/4885 |
| US-10738063-B2 | 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds | PDE4B, PDE5A, PDE3B | AGER 3434/4885VDR 3589/4885GAA 1441/4885 |
| US-20240294546-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2C | AGER 684/4885VDR 289/4885GAA 3389/4885 |
| US-11679095-B2 | Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases | CD68, PRNP, HTT | AGER 1155/4885VDR 4264/4885GAA 613/4885 |
| US-12358929-B2 | NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN2C | AGER 684/4885VDR 289/4885GAA 3389/4885 |
| US-20140140927-A1 | CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT | PSEN1, PSEN2, CROCC | AGER 359/4885VDR 1549/4885GAA 1525/4885 |
| US-20160263257-A1 | CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT | PSEN1, CROCC, PSEN2 | AGER 337/4885VDR 1711/4885GAA 1408/4885 |
| US-20200087323-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2C | AGER 684/4885VDR 289/4885GAA 3389/4885 |
| US-20220153755-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2C | AGER 684/4885VDR 289/4885GAA 3389/4885 |
| US-20120058049-A1 | CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT | CLN6, CA6, GALNT6 | AGER 747/4885VDR 2128/4885GAA 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.